Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response  New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series!
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 
Transcript:
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up.
Off to Seattle in a couple of days for MNO..
Okay.. our top story this week:
XX
Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.
The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms.
The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features.
Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here..
(clip)
I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration.
I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update.
XX
Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.
 
XX
SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective.
https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html
XX
Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes.
https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe
XX
A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1
diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10
 
XX
A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy.
T1d pregnancy and me study team, we did an episode on this.
XX
A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary.
https://www.sciencedaily.com/releases/2026/10/261017230031.htm
XX
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).
 
From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.
 
"Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shaping new treatments, and what people need from care today," said Dr Thomas Danne, Chief Medical Officer, International for Breakthrough T1D. "The most valuable discussions were the ones that connected those questions. That is how we make research more useful to the clinicians and communities it is meant to serve."
 
During CRC 2026, attendees explored the latest scientific and clinical advances during more than 80 sessions covering critical focus areas such as endocrinology, discovery science and immunotherapies, emerging technologies like AI and digital twins, islet cell and disease-modifying therapies, and access to care for the T1D community. Key moments from the two and half days of programming can be found in daily recaps below:
CRC 2026 Recap: Day 1
CRC 2026 Recap: Day 2
CRC 2026 Recap: Day 3 
We'll have more on this in an episode next week.
https://www.prnewswire.com/news-releases/breakthrough-t1d-concludes-inaugural-clinical--research-congress-highlighting-global-advances-in-type-1-diabetes-research-302906186.html
 
XX
Up next, Dexcom for type 2 and in athletes with T1D, technology news from omnipod and ascensia, and T1D takes the spotlight in the big leagues of baseball.. right after this.
XX
Ascensia Diabetes Care teams up with Sava Technologies to support the introduction and future commercialization of its wearable microsensor, currently under development. The technology is being designed to continuously monitor relevant biomarkers and molecules, starting with glucose, just beneath the skin.
Sava is planning for a pivotal clinical study for its CGM technology this year and aims to obtain CE approval and launch the microsensor within the next 18 to 24 months. Ascensia makes the CONTOUR® portfolio of blood glucose monitoring systems. They were partnered with Senseonics, the makers of the Eversense 365 implantable CGM but spun that business off last year
 
 
https://www.businesswire.com/news/home/20261008725757/en/Ascensia-Announces-Strategic-Partnership-with-Sava-for-Innovative-Microsensor-Technology
 
XX
Insulet Corporation announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs).
With Omnipod Discover, Omnipod 5 users get simple, personalized glucose and insulin delivery reports sent directly to their smartphone weekly, so they know where to focus their diabetes management efforts. Omnipod Discover also helps HCPs make confident clinical recommendations from a concise report by overlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events.
 
In June, Insulet presented Real-World Glycemic Outcomes1 using the Omnipod Discover platform at the American Diabetes Association's Scientific Sessions in New Orleans, Louisiana. Use of Omnipod Discover was associated with improvements in time in range (TIR), with 32% of users seeing a clinically meaningful increase in TIR of 3% or more. These findings support the vital role that user engagement with Omnipod Discover can play in diabetes self-management.
https://investors.insulet.com/news/news-details/2026/Insulet-Announces-Omnipod-Discover-Now-Available-in-U-S-/default.aspx
XX
We talked about this study with Dexcom in our bonus episode last week, but it's worth revisiting now that the results have been published in the New England Journal of Medicine. The Dexcom-funded study found that people with type 2 diabetes who don't use insulin saw significant improvements in blood sugar management when using a continuous glucose monitor. After 26 weeks, participants using Dexcom's G7 lowered their average A1C from 8.8% to 7.2%, compared to a drop from 8.7% to 8% for those receiving routine care. CGM users also spent about five additional hours each day in their target glucose range. The findings come as Medicare considers expanding CGM coverage to people with diabetes who don't use insulin, potentially opening access to millions more Americans. A decision on that expansion is expected before the end of the year, although the timing remains uncertain.
https://www.medtechdive.com/news/nejm-study-supports-cgm-use-for-people-with-diabetes-who-dont-take-insulin/833124/
 
XX
New research from Dexcom suggests that more young adults with type 1 diabetes are staying involved in sports, and feelings of isolation and stigma are declining. The percentage who quit sports after diagnosis dropped from 24% in 2022 to 16% in 2026, while those reporting frequent loneliness fell from 28% to 15%. But challenges remain, with fear of low blood sugar and the complexity of managing diabetes during exercise among the biggest reasons people stop playing. The research also found that young adults who started using a CGM within a year of diagnosis reported fewer glucose management challenges and less fear of lows than those who started later. The findings come as Dexcom launches its fifth season of Dexcom U, featuring 27 college athletes with diabetes across 13 sports. The program aims to increase visibility and show young people with T1D what's possible.
XX
Dexcom has announced a new partnership with Team Novo Nordisk, the world's only professional cycling team made up entirely of athletes with diabetes. Dexcom will become the team's official continuous glucose monitoring partner, with plans to support research, education, and awareness about managing type 1 diabetes during demanding physical activity. Team co-founder Phil Southerland says seeing professional athletes using the same diabetes technology as kids at home can make a powerful difference. Cyclist David Lozano, who's been with the team since 2012, says CGM technology has transformed how he trains, allowing him to see where his glucose is heading rather than just where it's been. The partnership also aims to highlight the role of diabetes technology in helping people with T1D pursue their athletic goals.
XX
A powerful moment in Major League Baseball this week as Milwaukee Brewers outfielder Garrett Mitchell, who was diagnosed with type 1 diabetes at age 9, hit the game-winning home run that sent his team to the World Series. Mitchell has faced doubts throughout his career about whether he could stay healthy enough to handle a full baseball season, but this year he's played more games than in his previous four seasons combined. His father, Antony, says Garrett has always been motivated to prove people wrong, and that managing diabetes behind the scenes takes tremendous work. Mitchell uses an insulin pump and monitors his glucose throughout games, and he's also become a role model for young athletes with T1D. His dad summed up the emotional moment this way: "He has managed himself for many years, and here he is, an example to kids that anything is possible." And now, after helping the Brewers complete a remarkable comeback against the Dodgers, Mitchell is headed to the World Series.
https://www.mlb.com/news/garrett-mitchell-hits-go-ahead-homer-to-send-brewers-to-world-series

A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.
So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?
I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 -  and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.
Our past episodes with Sernova here
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com

On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD  international conference. I'm asking your questions about longer sensor wear for kids, changes to adhesive, what's going on with the G8 and more.
 Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin.
This podcast is not meant at medical advice, if you have those types of questions, please ask your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections In the News…
A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.
Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.
 And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 
 
This week on Diabetes Connections In the News…
A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.
 
Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.
 
And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.
 
All that and more, coming up! It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Super excited to tell you that we have joined the Health Podcast Library! Over the years, I've been asked to join a lot of networks – and I've thought about starting my own – but this is the first one that made sense to me.  Health Podcast Library is a free place to find health podcasts from credible people and organizations. The creators and organizations producing each show are reviewed before it is listed. They believe sourcing matters. They don't pay me to be there and I'm proud to say I'm the first Diabetes Show featured on the Library to sign their The Health Content Integrity Pledge is a commitment from creators across all health topics and platforms to continuously work toward embedding evidence-based principles in their content creation and platform management. As creators of health-related content, we recognize our responsibility to provide accurate, transparent, and credible information that helps people make informed decisions about their health and well-being.
Go check it out and if you're a health podcaster, consider joining.
https://healthpodcastlibrary.com/
Health podcast networks
Okay.. our top story this week:
XX
Eli Lilly says an experimental drug combination helped people with obesity or overweight and type 2 diabetes lose an average of 23.3% of their body weight over 48 weeks, while also improving A1C. The treatment, called eloraTZP, combines the experimental drug eloralintide with Lilly's approved diabetes and weight-loss medication Zepbound. At the highest dose, participants lost an average of 54.1 pounds. The results are notable because people with type 2 diabetes typically lose less weight with obesity medications than people without diabetes.
The study included 367 adults with type 2 diabetes and obesity or overweight. The combination targets three hormones involved in blood sugar, digestion and appetite: GIP, GLP-1 and amylin. Side effects, mainly gastrointestinal, were more common with the combination, and as many as 27% of participants taking eloraTZP stopped treatment. Lilly plans to begin phase 3 trials later this year.
https://www.fiercebiotech.com/biotech/lilly-raises-weight-loss-bar-its-amylin-zepbound-combo
XX
New research suggests that for people with type 1 or type 2 diabetes, keeping glucose as steady as possible may not always translate into a better quality of life. In a study of 400 people with diabetes, researchers found that spending more time in the normal glucose range was associated with better quality of life the following day. Surprisingly, greater glucose variability was also linked to better next-day well-being, as long as glucose remained within safe limits.
The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan, do not suggest that high or low blood sugar is beneficial. Instead, researchers say they may point to a tradeoff in diabetes management: the effort and restrictions involved in trying to eliminate every glucose fluctuation could sometimes interfere with everyday activities and enjoyment of life. The study combined continuous glucose monitor data with daily assessments of mood, energy, sleep, stress and overall well-being.
https://www.sciencedaily.com/releases/2026/09/260927225019.htm
XX
New guidance from the American Diabetes Association and European Association for the Study of Diabetes puts a major focus on correctly diagnosing type 1 diabetes in adults. The report says about 40% of people diagnosed with type 1 after age 30 are initially misdiagnosed as having type 2 diabetes. It emphasizes that type 1 can develop at any age and that adults with the condition may have overweight or obesity, so age and body size alone shouldn't be used to determine diabetes type.
The updated guidance recommends islet autoantibody testing when type 1 diabetes is suspected and, in some cases, C-peptide testing to determine how much insulin the body is still producing. It also discourages use of the term "LADA," or latent autoimmune diabetes in adults, saying these cases are better classified as type 1 diabetes. The report also includes expanded guidance on diabetes complications, cardiovascular risk, obesity, exercise, nutrition and mental and emotional health.
https://www.medscape.com/viewarticle/guidance-type-1-diabetes-management-adults-updated-2026a1001080
XX
Eli Lilly says its once-daily GLP-1 pill Foundayo, also known as orforglipron, lowered A1C and weight while demonstrating cardiovascular safety in adults with type 2 diabetes and obesity or overweight who were at increased risk for heart problems. In the study, participants taking Foundayo lowered their A1C by 1.6 percentage points and lost an average of 8.8% of their body weight, or nearly 18 pounds, after one year. Those taking long-acting insulin lowered A1C by 1 percentage point and gained an average of 1.7% of their body weight.
 
Foundayo was also found to be at least as safe as insulin glargine when researchers looked at major cardiovascular events, including heart attack and stroke. The study also reported improvements in blood pressure, waist circumference and cholesterol, along with a slower decline in kidney function. The results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.
https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3
XX
A large Norwegian study found that type 1 diabetes diagnoses among young children increased after the country introduced routine rotavirus vaccination in 2014. Researchers followed more than 740,000 children and found that the rate of type 1 diabetes before age 5 was 11% higher than expected based on trends before the vaccine was introduced. The findings were presented at the European Association for the Study of Diabetes annual meeting and published in Diabetologia.
 
Importantly, the study does not show that the rotavirus vaccine causes type 1 diabetes. When researchers compared fully vaccinated children directly with unvaccinated children, the difference in type 1 diabetes risk was not statistically significant. Researchers had been studying the vaccine because infections, including rotavirus, have been investigated as possible environmental factors affecting type 1 diabetes risk, and previous studies have produced conflicting results.
https://www.news-medical.net/news/20261001/Type-1-diabetes-incidence-rose-by-1125-after-rotavirus-vaccine-rollout-in-Norway.aspx
XX
A large study of children with type 1 diabetes found that very low- and low-carbohydrate diets were associated with better blood sugar control and lower insulin needs, without evidence of impaired growth or increased rates of severe low blood sugar or diabetic ketoacidosis. The research included more than 45,000 children ages 1 to 17 and used up to 25 years of data. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.
 
Children eating fewer carbohydrates also had smaller increases in BMI and A1C over time compared with those eating standard or higher-carbohydrate diets. However, researchers emphasized that this was an observational study, meaning it cannot prove that eating fewer carbohydrates caused these improvements. They say more research is needed to determine the long-term safety of these diets and how much carbohydrate may provide benefits while still supporting good nutrition and food variety.
https://medicalxpress.com/news/2026-10-carbohydrate-diets-linked-health-benefits.html
XX
A structured diet and exercise program helped about half of younger adults with type 2 diabetes achieve remission, according to research presented at the European Association for the Study of Diabetes annual meeting in Milan. The study focused on adults ages 18 to 45 with obesity and early-onset type 2 diabetes, a form of the condition associated with faster progression and earlier complications.
Participants in the program followed a low-calorie diet of 800 to 900 calories per day for 12 weeks, along with supervised aerobic and strength training, before transitioning to a weight-maintenance diet and independent exercise. At 24 weeks, researchers measured how many participants had an A1C below 6.5% without taking glucose-lowering medication for at least 12 weeks. The researchers compared those results with participants receiving usual diabetes care.
https://medicalxpress.com/news/2026-10-calorie-diet-early-onset-diabetes.html
XX
The FDA has approved Eli Lilly's Onswik, a once-weekly long-acting insulin for adults with type 2 diabetes. Instead of taking a daily basal insulin injection, people using Onswik will take one injection per week, potentially eliminating more than 300 injections a year. In studies involving more than 3,400 adults with type 2 diabetes, Onswik lowered A1C by amounts comparable to daily long-acting insulin.
Onswik is expected to become available in the U.S. in the coming months in pre-filled insulin pens. The insulin is approved for type 2 diabetes only and should not be used by people with type 1 diabetes because of an increased risk of severe low blood sugar. Onswik has already been approved in Europe, Japan and Mexico.
Onswik joins Novo's Awiqly – which I have to say are two of the more entertaining drugs names we've seen this year.
 
https://www.reuters.com/legal/litigation/us-fda-approves-lillys-once-weekly-insulin-injection-type-2-diabetes-2026-09-24/
XX
Two small studies looked at how different physical activity affects glucose levels in people with type 1 diabetes. In one, researchers tracked 110 instances of sexual activity among 12 adults using continuous glucose monitors and found no clinically significant hypoglycemia, even when sex occurred at night. Glucose sometimes rose and sometimes fell, suggesting there isn't one predictable glucose response to sexual activity.
A separate study followed 10 runners with type 1 diabetes as they completed a marathon alongside 10 runners without diabetes. All of the runners with T1D finished, with times comparable to the control group, although one runner had two low blood sugar readings. Researchers also found that CGMs became less accurate during the marathon and suggested using a glucose meter when sensor readings don't match how a runner feels. Both studies were small, but researchers say the findings could help address fear of hypoglycemia, which can affect everything from exercise to intimacy.
https://medicalxpress.com/news/2026-09-sex-safe-diabetes-small-glucose.html
http://medicalxpress.com/news/2026-09-marathons-diabetes-safe-small.html#goog_rewarded
XX
We told you about Beta Bionics iLet new compatibility with Senseonic's  Eversense 365 CGM.. now the companies announce the MINT tubeless pump will also work with the year-long implantable CGM.
Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users.
The companies have also committed to the integration of mint and Eversense 365 in the future. This partnership underscores Beta Bionics' and Senseonics' shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes.
https://investors.betabionics.com/news-releases/news-release-details/beta-bionics-announces-agreement-integrate-iletr-bionic-pancreas
XX
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom.
No word yet on the tubeless Mobi – still waiting to hear from the FDA on that.
Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,* and a 200-unit cartridge.
https://www.businesswire.com/news/home/20260928831177/en/Tandem-Mobi-Automated-Insulin-Delivery-System-Now-Available-in-Twelve-International-Markets
XX
Many people with type 2 diabetes still face barriers to using continuous glucose monitors, according to a new report from Dexcom. The company surveyed about 2,500 people with type 2 diabetes and more than 800 healthcare professionals across eight countries. More than half of people with diabetes said they knew little about CGM as a management option, while healthcare professionals pointed to insurance coverage and reimbursement as major barriers to access.
Among people with type 2 diabetes already using CGM, 94% said the technology helped them manage their diabetes more independently and 91% said they used CGM data to help make treatment decisions. The report also found limited awareness of using CGM alongside GLP-1 medications: 72% of people with type 2 diabetes surveyed did not know the two could be used together. The findings were released by Dexcom ahead of the European Association for the Study of Diabetes annual meeting in Milan.
https://www.medicaldevice-network.com/news/dexcom-report-paints-mixed-picture-of-cgm-use-by-people-with-type-2-diabetes/?cf-view
XX
Dexcom is facing a handful of lawsuits, alleging the company's CGMs malfunctioned and caused severe medical emergencies in children.
The latest lawsuits involve a 7-year-old California girl and a 10-year-old Tennessee girl who were both hospitalized after their Dexcom G7 devices allegedly failed to accurately report blood glucose levels.
The legal firm behind 11 of these suits say they involved G7 and G6 CGMs with plantiffs in six states.
https://www.mddionline.com/diabetes/dexcom-faces-lawsuit-alleging-device-failures-endangered-children
 
XX
Frances Valentine, the fashion brand created by the late Kate Spade and her friend Elyce Arons, is dipping into the glamorous world of old Hollywood with a new Mary Tyler Moore collection that pays homage to the actress.
The limited-edition capsule features 20 pieces, including shirts, dresses, tote bags and, of course, shoes, all inspired by the Emmy-winning star's whimsical, upscale style. Prices start at $48 for a makeup clutch and go up to $498 for wool peacoats.
The lineup was co-created with the Mary Tyler Moore Vision Initiative, an organization dedicated to "preserving and restoring vision in people with diabetes," per the nonprofit's website. Twenty percent of proceeds from the collection will benefit the cause, which was particularly meaningful to Moore.
Type 1 diabetes is an autoimmune condition in which the pancreas produces little or no insulin, while Type 2 diabetes is a metabolic disorder. Other public figures who have spoken about living with Type 1 diabetes include model Lila Moss, Dancing With the Stars pro Rylee Arnold and musician Nick Jonas.
The Mary Tyler Moore Vision Initiative was established by Moore's husband, Dr. S. Robert Levine, following her death in 2017.
https://www.hollywoodreporter.com/lifestyle/shopping/mary-tyler-moore-frances-valentine-clothing-collection-2026-1236714592/
XX
The FDA has cleared a new app that uses continuous glucose monitor and insulin data to recommend insulin dose adjustments directly to adults with type 2 diabetes who take insulin by injection. The app, called MODI and developed by DreaMed Diabetes, can provide personalized recommendations without requiring a healthcare provider to review or approve each individual dose change.
MODI is designed for adults with type 2 diabetes who use long-acting insulin, either alone or with rapid-acting insulin. While automated insulin dosing technology has largely focused on people using insulin pumps, MODI brings automated dosing support to people who use injections. The goal is to help adjust insulin more frequently between healthcare visits, rather than waiting weeks or months for a provider to make changes.
Interesting name – there is a type of diabetes called MODY - Maturity-Onset Diabetes of the Young (MODY) is a rare, inherited form of diabetes caused by a single gene mutation that affects how the pancreas makes insulin.
https://dreamed.ai/press-releases/dreamed-receives-fda-clearance-for-modi/
https://diabetes-connections.com/we-treat-the-data-lifting-the-burden-of-diabetes-with-dreamed/

On this bonus episode of diabetes connections, we're talking about the Beyond Barriers Innovation Accelerator. This is a project from Beyond Type 1 which is investing in community-based organizations and entrepreneurs working to close those gaps. We'll hear about some really interesting projects from comic books for kids to apps for first responders and programs to help with cost…
And we'll zoom out: eleven years after Beyond Type 1 launched, what is the organization today—and how is it trying to make sure more people with diabetes have the opportunity not just to survive, but to thrive? What's the mission for Beyond Type 1 in 2026?
This podcast is not intended as medical advice, if you have those kinds of questions, please contact your healthcare provider.
More about the Innovation Accelerator and Beyond Type 1 here
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com